OBJECTIVES: To evaluate the value of a new treatment of moderate-severe plaque psoriasis, Ixekizumab, compared to the main therapeutic alternatives through MCDA.

METHODS: Available evidence of Ixekizumab as well as its therapeutic alternatives in the same indication: Evaluations of the Hospital Genesis Group, guidelines of clinical practice, public document of European evaluation (EPAR) and other evaluations for Societies and Institutions in Spain.

EVIDEM framework weighted by a total of 45 national and regional evaluators in Spain was used. Evidence Matrix were scored by a panel of 5 experts; 2 hospital pharmacists, 1 regional payer, 1 psoriasis expert and 1 patient representative.

RESULTS: Moderate-severe plaque psoriasis was perceived as a disease of moderate severity, affecting a large population size and with some unmet needs. In case of comparative efficacy/effectiveness (PASI90 and PASI100) and patient-perceived health (including posology and quality of life) ixekizumab was perceived as a value option in front of its comparators. Comparative safety and tolerability was perceived as similar for all the alternatives. Regarding, the therapeutic benefit, ixekizumab was considered as a drug able to add value. The proposed cost of ixekizumab, other medical costs, and also of non-medical costs, in general, were considered as positive. The global value contribution of ixekizumab, compared with its comparators were: secukinumab (0.36), ustekinumab (0.38), etanercept (0.44) and adalimumab (0.45).

CONCLUSIONS: The MCDA has demonstrated that it is a useful tool to compare the value of the several treatments in Psoriasis. Ixekizumab would be perceived as a valuable option in the treatment of moderate-severe plaque psoriasis compared with current alternative treatment. The main contribution of value would be based on its therapuetic benefit and efficacy (measured in terms of a response to PASI90 and PASI100 and maintenance of a long term), also valued because the easy posology and quality of life data.